Success Metrics

Clinical Success Rate
93.8%

Based on 30 completed trials

Completion Rate
94%(30/32)
Active Trials
3(8%)
Results Posted
63%(19 trials)
Terminated
2(6%)

Phase Distribution

Ph not_applicable
2
6%
Ph phase_2
6
17%
Ph early_phase_1
1
3%
Ph phase_3
4
11%
Ph phase_1
4
11%
Ph phase_4
17
47%

Phase Distribution

5

Early Stage

6

Mid Stage

21

Late Stage

Phase Distribution34 total trials
Early Phase 1First-in-human
1(2.9%)
Phase 1Safety & dosage
4(11.8%)
Phase 2Efficacy & side effects
6(17.6%)
Phase 3Large-scale testing
4(11.8%)
Phase 4Post-market surveillance
17(50.0%)
N/ANon-phased studies
2(5.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.8%

30 of 32 finished

Non-Completion Rate

6.3%

2 ended early

Currently Active

3

trials recruiting

Total Trials

36

all time

Status Distribution
Active(3)
Completed(30)
Terminated(2)
Other(1)

Detailed Status

Completed30
Recruiting3
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
36
Active
3
Success Rate
93.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (2.9%)
Phase 14 (11.8%)
Phase 26 (17.6%)
Phase 34 (11.8%)
Phase 417 (50.0%)
N/A2 (5.9%)

Trials by Status

recruiting38%
terminated26%
completed3083%
unknown13%

Recent Activity

Clinical Trials (36)

Showing 20 of 36 trialsScroll for more
NCT05170399Phase 4

Vaccine Responses in Patients With B Cell Malignancies

Recruiting
NCT04101838Phase 4

B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults

Recruiting
NCT05291676Phase 2

Systems Investigation of Vaccine Responses in Aging and Frailty

Recruiting
NCT02871206Phase 4

Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children

Completed
NCT03722589Phase 4

Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP

Completed
NCT02918006Phase 2

A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine

Completed
NCT03068949Phase 4

Comparison of Three Licensed Influenza Vaccines

Completed
NCT03453801Phase 1

The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection

Completed
NCT03028974Phase 4

Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)

Completed
NCT00980005Phase 3

Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children

Completed
NCT01974895Phase 2

Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age

Completed
NCT00764790Phase 3

Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children

Completed
NCT00383123Phase 3

Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in Children

Completed
NCT03020498Phase 4

B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)

Completed
NCT03020537Phase 4

B-cell Immunity to Influenza (SLVP017)- Year 5, 2013

Completed
NCT01685372Phase 2

Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults

Completed
NCT00538512Phase 4

Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4

Completed
NCT00902278Not Applicable

Immune Responses Induced by Different Licensed Influenza Vaccines

Completed
NCT03028987Phase 4

Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)

Terminated
NCT01389479Phase 3

Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Healthy Adults

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
36